Cell Senescence in Myxoid/Round Cell Liposarcoma

Autor: Christina Kåbjörn Gustafsson, Anders Ståhlberg, Katarina Engtröm, Anna Danielsson, Ingela Turesson, Pierre Åman

Publikováno v: Sarcoma, Vol 2014 (2014)

Myxoid/round cell liposarcoma (MLS/RCLS) is the second most common liposarcoma type and characterized by the fusion oncogenes FUS-DDIT3 or EWSR1-DDIT3. Previous analysis of cell cycle regulatory proteins revealed a prominent expression of G1-cyclins,

Externí odkaz: https://doaj.org/article/07ac57bbb500495d9a593eff3eabc20e

Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity.

Autor: J Peter Svensson, Lukas J A Stalpers, Rebecca E E Esveldt-van Lange, Nicolaas A P Franken, Jaap Haveman, Binie Klein, Ingela Turesson, Harry Vrieling, Micheline Giphart-Gassler

Publikováno v: PLoS Medicine, Vol 3, Iss 10, p e422 (2006)

BackgroundRadiation is an effective anti-cancer therapy but leads to severe late radiation toxicity in 5%-10% of patients. Assuming that genetic susceptibility impacts this risk, we hypothesized that the cellular response of normal tissue to X-rays c

Externí odkaz: https://doaj.org/article/d32c69526bc34532b1133fcd15a5f9c8

Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer

Autor: Lars Holmberg, Fredrik Sandin, Ingela Turesson, Lennart Åström, Erik Grusell

Publikováno v: Radiotherapy and Oncology. 127:81-87

High-dose-rate brachytherapy (HDR-BT) has optimal prerequisites in radiotherapy of prostate cancer (PC) with a conformal dose distribution and high doses per fraction giving a biological dose escalation. We report the outcome after HDR-BT and externa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbadd884563d1116bd66864d23a6788d
https://doi.org/10.1016/j.radonc.2017.12.025

UV-Radiation Response Proteins Reveal Undifferentiated Cutaneous Interfollicular Melanocytes with Hyperradiosensitivity to Differentiation at 0.05 Gy Radiotherapy Dose Fractions

Autor: Per, Fessé, Fredrik, Qvarnström, Jan, Nyman, Ingegerd, Hermansson, Johan, Ahlgren, Ingela, Turesson

Publikováno v: Radiation research. 191(1)

To date, the response activated in melanocytes by repeated genotoxic insults from radiotherapy has not been explored. We hypothesized that the molecular pathways involved in the response of melanocytes to ionizing radiation and ultraviolet radiation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e2c156fc558f0dfeec03f15bfeb1c98b
https://pubmed.ncbi.nlm.nih.gov/30407899

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Autor: W. J. Chng, Michele Cavo, Shaji Kumar, Chang-Ki Min, Xavier Leleu, Charalampia Kyriakou, Sundar Jagannath, M.V. Mateos, Daniel D Waller, Je-Jung Lee, Ravi Vij, Evangelos Terpos, Chaim Shustik, Jens Hillengass, Heinz Ludwig, Dominik Dytfeld, Brian G.M. Durie, Parameswaran Hari, Hareth Nahi, Meral Beksac, Laura Rosiñol, Philippe Moreau, Ashraf Badros, Jin Seok Kim, Saad Z. Usmani, Ingela Turesson, Markus Hansson, Hyeon Seok Eom, H. Goldschmidt, Albert Oriol, E Kastritis, Tomer M Mark, Meletios A. Dimopoulos, Michel Delforge, J.J. Lahuerta, Elizabeth O'Donnell, J de la Rubia, Melissa Alsina, Paula Rodriguez Otero, Je-Hwan Lee, Ki-Hyun Kim, Ulf-Henrik Mellqvist, Henk M. Lokhorst, N W C J van de Donk, Shuji Ozaki, Enrique M. Ocio, Anna Sureda

Publikováno v: LEUKEMIA
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Leukemia, 31(11), 2443-2448. Nature Publishing Group
Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, Van De Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J J, De La Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S & Durie, B G M 2017, ' Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : A multicenter IMWG study ', Leukemia, vol. 31, no. 11, pp. 2443-2448 . https://doi.org/10.1038/leu.2017.138

Background: Treatment of multiple myeloma has evolved considerably in the past few years with availability of several news drugs as well as increasing use of multidrug combinations. These changes have no doubt led to the improved survival seen among

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6b476bc2bffe04a101a2f4419b785b
http://hdl.handle.net/11585/614587